Attovia Therapeutics Inc. , an early-stage drug developer focused on immune system diseases with high unmet need, raised $289 million in a US initial public offering that priced at the top of its marketed range.

Source: [Bloomberg Markets](https://www.bloomberg.com/news/articles/2026-08-05/goldman-backed-biotech-attovia-raises-289-million-in-us-ipo)

Sponsored